These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3107906)

  • 21. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175.
    Sato S; Mori K; Wyman M; Kador PF
    Exp Eye Res; 1998 Feb; 66(2):217-22. PubMed ID: 9533847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE; Larsen AB; Gregersen G
    Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract]   [Full Text] [Related]  

  • 23. Direct stimulation of Na+-K+-ATPase and its glucosylated derivative by aldose reductase inhibitor.
    Garner MH; Spector A
    Diabetes; 1987 Jun; 36(6):716-20. PubMed ID: 3032716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose inhibition of human fibroblast proliferation and response to growth factors is prevented by inhibitors of aldose reductase.
    Sibbitt WL; Mills RG; Bigler CF; Eaton RP; Griffey RH; Vander Jagt DL
    Mech Ageing Dev; 1989 Mar; 47(3):265-79. PubMed ID: 2497284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
    Vinores SA; Campochiaro PA
    Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corneal permeability of aldose reductase inhibitor, M79175. II. In vivo study on pharmacokinetic aspect.
    Kato A; Horie T; Ishibashi Y; Miyake Y; Iwata S
    J Ocul Pharmacol; 1986; 2(3):287-94. PubMed ID: 3139809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorbinil: a member of the novel class of spirohydantoin aldose reductase inhibitors.
    Sarges R; Peterson MJ
    Metabolism; 1986 Apr; 35(4 Suppl 1):101-4. PubMed ID: 3083199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human kidney aldose and aldehyde reductases.
    Sato S; Kador PF
    J Diabetes Complications; 1993; 7(3):179-87. PubMed ID: 8343612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E
    Diabetes; 1985 Jan; 34(1):15-21. PubMed ID: 3917257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The polyol pathway in retinal microangiopathy.
    Robison WG; Kinoshita JH; Kador PF
    Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
    Nakano T; Petrash JM
    Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.
    Christensen JE; Varnek L; Gregersen G
    Acta Neurol Scand; 1985 Feb; 71(2):164-7. PubMed ID: 3920861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ponalrestat: a potent and specific inhibitor of aldose reductase.
    Ward WH; Sennitt CM; Ross H; Dingle A; Timms D; Mirrlees DJ; Tuffin DP
    Biochem Pharmacol; 1990 Jan; 39(2):337-46. PubMed ID: 2105733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors.
    Kador PF; Akagi Y; Takahashi Y; Ikebe H; Wyman M; Kinoshita JH
    Arch Ophthalmol; 1990 Sep; 108(9):1301-9. PubMed ID: 2119169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The aldose reductase inhibitor site.
    Kador PF; Kinoshita JH; Sharpless NE
    Metabolism; 1986 Apr; 35(4 Suppl 1):109-13. PubMed ID: 3083201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-performance liquid chromatographic analysis of glucose, fructose, sorbitol and low levels of the aldose reductase inhibitor sorbinil in human lens and plasma.
    Lloyd P; Crabbe MJ
    J Chromatogr; 1985 Oct; 343(2):402-6. PubMed ID: 3934205
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors.
    Rizzi JP; Schnur RC; Hutson NJ; Kraus KG; Kelbaugh PR
    J Med Chem; 1989 Jun; 32(6):1208-13. PubMed ID: 2498517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
    Lightman S; Rechthand E; Terubayashi H; Palestine A; Rapoport S; Kador P
    Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.